International Multicenter Retrospective Study From the Ultra-rare Sarcoma Working Group on Low-grade Fibromyxoid Sarcoma, Sclerosing Epithelioid Fibrosarcoma, and Hybrid Forms
Authors:
- Claudia GianiCGClaudia Giani
- Abdulazeez SalawuASAbdulazeez Salawu
- Silva Msc LjevarSLSilva Msc Ljevar
- Ryan A. DenuRDRyan A. Denu
- Andrea NapolitanoANAndrea Napolitano
- Emanuela PalmeriniEmanuela Palmerini
- Elizabeth A. ConnollyECElizabeth A. Connolly
- Koichi OguraKOKoichi Ogura
- Daniel D. WongDWDaniel D. Wong
- Roberto ScanferlaRSRoberto Scanferla
- Evan RosenbaumEREvan Rosenbaum
- Jyoti BajpaiJBJyoti Bajpai
Open Access
- 28 October 2024
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 49 (1) , 27-34
Abstract
The aim of the study was to report the outcome of primary localized low-grade fibromyxoid sarcoma (LGFMS), sclerosing epithelioid fibrosarcoma (SEF), and hybrid LGFMS/SEF (H-LGFMS/SEF). Patients with primary localized LGFMS, SEF, or H-LGFMS/SEF, surgically treated with curative intent from January 2000 to September 2022, were enrolled from 14 countries and 27 institutions. Pathologic inclusion criteria were predefined by expert pathologists. The primary endpoint was overall survival (OS). Secondary endpoints were crude cumulative incidence (CCI) of local recurrence (LR), CCI of distant metastases (DM), and post-metastases OS (p-OS). Two hundred ninety-four patients (239 LGFMS, 32 SEF, and 23 H-LGFMS/SEF) were identified. At a median(m-) follow-up (FU) of 57.1 months, 12/294 patients died. The 5- and 10-year OS were 99.0% and 95.9% in LGFMS, 86.2% and 67.0% in SEF, and 84.8% and 84.8% in H-LGFMS/SEF, respectively. Predictors of worse OS included pathology, age at surgery, systemic therapy, and radiotherapy. LR developed in 13/294 (4.4%) patients. The observed m-time to LR was 10.7 months. The 5- and 10-yr CCI-LR were 4.7% in LGFMS and 6.6% in SEF, respectively. There were no LR events in H-LGFMS/SEF. The sole predictor of higher risk of LR was histology. DM developed in 23/294 (7.8%) patients. The observed m-time to DM was 28.2 months. The 5- and 10-yr CCI-DM were 1.3% and 2.7% in LGMFS, 29.9% and 57.7% in SEF, 48.9% and 48.9% in H-LGFMS/SEF, respectively. Predictors of higher risk of DM were histology, systemic therapy, and radiotherapy. Primary localized LGFMS treated with complete surgical resection has an excellent prognosis, while about 50% of H-LGFMS/SEF and SEF develop DM within 5 to 10 years. Very long-term FU is needed to understand absolute cure rates.Keywords
This publication has 15 references indexed in Scilit:
- Uncommon and peculiar soft tissue sarcomas: Multidisciplinary review and practical recommendations for diagnosis and treatment. Spanish group for Sarcoma research (GEIS – GROUP). Part ICancer Treatment Reviews, 2021
- Ultra‐rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entitiesCancer, 2021
- Clinical Characteristics and efficacy of chemotherapy in sclerosing epithelioid fibrosarcomaMedical Oncology, 2018
- A genetic dichotomy between pure sclerosing epithelioid fibrosarcoma (SEF) and hybrid SEF/low‐grade fibromyxoid sarcoma: A pathologic and molecular study of 18 casesGenes, Chromosomes and Cancer, 2014
- Recurrent EWSR1-CREB3L1 Gene Fusions in Sclerosing Epithelioid FibrosarcomaAmerican Journal of Surgical Pathology, 2014
- MUC4 Is a Sensitive and Extremely Useful Marker for Sclerosing Epithelioid FibrosarcomaAmerican Journal of Surgical Pathology, 2012
- FUS rearrangements are rare in ‘pure' sclerosing epithelioid fibrosarcomaLaboratory Investigation, 2012
- Low-Grade Fibromyxoid SarcomaAmerican Journal of Surgical Pathology, 2011
- MUC4 Is a Highly Sensitive and Specific Marker for Low-grade Fibromyxoid SarcomaAmerican Journal of Surgical Pathology, 2011
- The chimeric FUS/CREB3l2 gene is specific for low‐grade fibromyxoid sarcomaGenes, Chromosomes and Cancer, 2004